MedTech Elects Seven New Members to Board of Directors
Monday, October 28, 2013
SYRACUSE, N.Y., Oct. 28, 2013—The MedTech Association, the hub of New York State's bioscience and medical technology industry, has added seven highly-qualified community and industry leaders to its 2013-2014 board of directors. MedTech appreciates the distinguished efforts of its 2012-2013 board and looks forward to advancing the organization's mission with its new directors.
For a complete listing of MedTech directors, visithttp://www.medtech.org/about/board.aspx.
Two Syracuse-area executives were named to the board:
Chief Executive Officer, Volpi Manufacturing USA
Max started his career as an electrical apprentice in Switzerland. Following his apprenticeship, he received a bachelor's degree in electrical engineering from the Polytechnic School in Winterthur/Zurich. Throughout his 30 year career, Max Kunz always possessed the desire to be an entrepreneur and a business owner.
After several years of practical experience working in the industry for ABB in Switzerland, both as an engineer and director of sales for the Americas, Max pursued and received his MBA from Nova University in the US. Following his time at ABB, Max held different management positions for Zühlke Engineering in Switzerland before he was presented with the opportunity to take over the Volpi Group in 2008. Max’s main roles at Volpi are to provide operations oversight and to lead the sales and marketing efforts to propel Volpi’s OEM business in the life science and medical markets.
Jack Rudnick is an experienced corporate and intellectual property attorney who has been providing legal counsel for almost 40 years. Rudnick co-founded Blue Highway, Inc. while at Welch Allyn, Inc. to locate and accelerate the development of technologies with medical applications. He served as Blue Highway's senior vice president of legal and government affairs. He is currently of counsel with Hiscock & Barclay's Emerging Technology Team, where he provides business and legal consultation to technology-based companies. Prior to his appointment as director of the Technology Commercialization Law Program, Rudnick contributed to the program as an adjunct professor, assisting Founding Director Ted Hagelin in the Commercialization Research Center from 2011 until 2013. He is an active member of several professional organizations, including the American Bar Association, New York State Bar Association, and the Association of Corporate Counsel (past president of Central and Western New York chapter).
One Albany-area executive was named to the board:
President and CEO, AngioDynamics
Joseph DeVivo joined AngioDynamics in Sept. 2011. Previously, he was CEO and president of RITA Medical Systems, which he transitioned from an ablation company to the leader in medical device oncology. AngioDynamics acquired RITA in 2006, and its products formed much of AngioDynamics' division of oncology/surgery, which has been a key driver of the company's growth. DeVivo most recently served as global president of Smith & Nephew Orthopedics, where he successfully led its $2 billion global orthopedics business to record growth.
Prior to RITA Medical Systems, DeVivo served as president, COO and director of Computer Motion Incorporation (CMI), leading a turnaround and successful merger with Intuitive Surgical, Inc. DeVivo previously served as vice president and general manager of a $350 million division of TYCO International's healthcare business, U.S. Surgical/Davis and Geck Sutures, where he was responsible for sales, marketing, R&D, and finance in its vascular business. DeVivo earned his bachelor's in business administration from the E. Claiborne Robins School of Business at the University of Richmond.
Two Rochester-area executives were named to the board:
Kimberly Briggs is the Vice President of Regulatory Affairs for the surgical and vision care businesses of the B+L division of Valeant Pharmaceuticals International, Inc. Kimberly has more than 16 years of both regulatory and quality experience in medical devices, with positions held at Greatbatch Medical, St. Jude Medical and Boston Scientific.
VP - Marketing, North America, Getinge Infection Control
Jim Gabalski is the North America Vice President of Marketing for Getinge Infection Control, a division of The Getinge Group. As a global leader in healthcare solutions, Getinge Infection Control provides infection control products and services to the healthcare market with a specific focus on acute care facilities. In each of Getinge Group’s divisions, including Maquet and Arjo Huntleigh, Getinge is recognized for innovations that ensure patient safety and deliver positive patient outcomes. Jim is a long-time upstate NY resident. His career has been mostly spent in the Rochester area while working with global brands such as T-Mobile, Cisco, Jim Beam, Gucci, Siemens, and many others. His blend of sales, sales leadership, and marketing experiences as well as his passion for healthcare led him to Getinge in December of 2010. Under Jim’s leadership, the North America Infection Control marketing team has launched over 30 new commercial offerings in less than 30 months. These include innovations in surgical instrument cleaning, decontamination, and sterilization as well as programs that bundle offerings in a unique way to deliver superior value to Getinge customers. By combining the innovation of a Rochester company with the sales and marketing prowess of Getinge is a combination that can drive significant change for patients in North America.
One Buffalo-area executive was named to the board:
Chief Executive Officer, SoPark Corporation
Gerry is now the sole owner, CEO and chairman of the board of SoPark, an ISO 9001:2008, AS 9100 and ISO 13485 certified contract electronics service provider. He is also the founder, president & CEO of a new high tech venture, Precision Scientific Instruments, Inc. (PSi™), which is commercializing disruptive US-patented technologies. Prior to starting his management consulting firm, Murak & Associates LLC in 1991, he turned around the performance within two different locations of a Fortune 500 FDA regulated corporation, as well as a top-100 Western New York corporation. He is currently a member of the University at Buffalo (UB) School of Management (SOM) Dean’s Advisory Council and a Director on the UB SOM Alumni Board. Gerry Murak has an MS, MBA and Certified Professional designation in human resources. He is also a professional speaker and author of several journal articles.
One Boston-area executive was named to the board:
Vice President and General Manager, Corning Life Sciences
Dr. Richard Eglen joined Corning with more than 33 years experience in the life science industry including his most recent role as president of bio-discovery at PerkinElmer, Inc. Previously, he was vice president and general manager at Drug Discovery Reagents within PerkinElmer. Prior to joining PerkinElmer, he held numerous executive management positions in the pharmaceutical, diagnostic, and biotech industries. Until 2006, Richard was executive vice president for research and development at DiscoveRx Corp. He also served as vice president of the Center for Biological Research at Roche. Richard received his bachelor's degree in special honours physiology from Sheffield University, UK and a Ph.D. in molecular pharmacology from Trent University, UK.
MedTech is an active New York State association of pharmaceutical, biotech, and medical technology companies, their suppliers and service providers, and research universities. We boost the growth and prosperity of our members by connecting them for collaboration, offering educational programs, sharing news and information, and advocating for the industry with government and leaders. For more information, visit http://www.medtech.org.